ArticleCancers2011
Cancer genome sequencing and its implications for personalized cancer vaccines.
Article in Cancers, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges.Clinical and experimental medicine · 2026Review
- Individualized mRNA Vaccines in Melanoma-Where Do We Stand?Vaccines · 2025Review
- The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Journal of hematology & oncology · 2025Review
- Progress in the development of cancer vaccines for lung cancer utilizing dendritic cells (Review).Oncology letters · 2025Review
- Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity.Vaccines · 2025Review
- Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy.Molecular biotechnology · 2025Review
- Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.Biomolecules · 2024Review
- Advanced T and Natural Killer Cell Therapy for Glioblastoma.Journal of Korean Neurosurgical Society · 2023Article
- The future of cancer immunotherapy: DNA vaccines leading the way.Medical oncology (Northwood, London, England) · 2023Review
- Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities.Frontiers in immunology · 2023Review
- Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.Journal for immunotherapy of cancer · 2021Article
- Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.Genome medicine · 2021Article
- The Role of Neoantigens in Cancer Immunotherapy.Frontiers in oncology · 2021Review
- Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications.Frontiers in oncology · 2021Review
- Progress in Neoantigen Targeted Cancer Immunotherapies.Frontiers in cell and developmental biology · 2020Review
- Neoantigen vaccine: an emerging tumor immunotherapy.Molecular cancer · 2019Review
- Preclinical and clinical development of neoantigen vaccines.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Review
- Breast Cancer Neoantigens Can Induce CD8Cancer immunology research · 2017Article
- Review
- Construction of random tumor transcriptome expression library for creating and selecting novel tumor antigens.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New DNA sequencing platforms have revolutionized human genome sequencing. The dramatic advances in genome sequencing technologies predict that the $1,000 genome will become a reality within the next few years. Applied to cancer, the availability of cancer genome sequences permits real-time decision-making with the potential to affect diagnosis, prognosis, and treatment, and has opened the door towards personalized medicine. A promising strategy is the identification of mutated tumor antigens, and the design of personalized cancer vaccines. Supporting this notion are preliminary analyses of the epitope landscape in breast cancer suggesting that individual tumors express significant numbers of novel antigens to the immune system that can be specifically targeted through cancer vaccines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.